Do Not Test for Cure After C. difficile Treatment
Testing after completing treatment for Clostridioides difficile infection (CDI) has no clinical value and should not be performed, as more than 60% of successfully treated patients will remain test-positive. 1
Key Principle: Test-of-Cure is Not Recommended
The 2018 IDSA/SHEA guidelines explicitly state there is no clinical value in repeat CDI testing to establish cure, with studies showing that >60% of patients remain C. difficile positive even after successful treatment. 1 This recommendation is echoed in the 2015 JAMA systematic review, which clearly states that "test of cure" is not recommended after CDI treatment. 2
Timeline for Test Conversion During Treatment
When testing is performed during active treatment (which should be avoided), conversion rates are as follows:
- After 1 day of treatment: 14% of PCR tests convert to negative 3
- After 2 days of treatment: 35% convert to negative 3
- After 3 days of treatment: 45% convert to negative 3
However, these data underscore why post-treatment testing is problematic—the majority of patients remain positive despite clinical cure. 3
When Testing Should Be Performed
Do NOT Test:
- Within 7 days during the same diarrhea episode (strong recommendation, moderate quality evidence) 1
- Asymptomatic patients (except for epidemiological studies) 1
- To establish cure after treatment completion 1, 2
DO Test:
- Only if new symptoms develop after successful treatment and diarrhea cessation, as this may represent true recurrence requiring confirmation 1
- Testing for recurrent CDI should ideally include toxin detection, as persistence of toxigenic C. difficile can occur commonly after infection 1
- In one study, 35% of CDI patients with recurrent diarrhea tested negative for toxin, highlighting that empiric treatment without confirmatory testing is discouraged 1
Clinical Implications
Base treatment success on clinical resolution of symptoms (cessation of diarrhea), not on laboratory test results. 1, 2 Patients can experience altered bowel habits and reduced health scores for months after CDI, which should not prompt repeat testing in the absence of true diarrhea recurrence. 1
Special Consideration for IBD Patients
In patients with inflammatory bowel disease (IBD), symptoms related to CDI may overlap with IBD flare symptoms, creating diagnostic challenges. In this specific population, repeated testing in patients with ongoing symptoms may be necessary to guide management, despite the risk of false-positive results. 4
Common Pitfall to Avoid
Empirical CDI therapy before specimen collection can result in false-negative tests. If empirical treatment is given, 44% of patients who were truly positive at the time of test order converted to negative PCR results by the time stool specimens were collected, compared to 0% without empirical therapy. 3 This reinforces that testing should occur before treatment initiation when possible, but post-treatment testing remains inappropriate.